Imlygic

talimogene laherparepvec

Approval

ApplicationBLA 125518
Approval dateDec 8, 2021
Approval year2021
SponsorBioVex Inc., a wholly owned subsidiary of Amgen, Inc

FDA-approved use

For the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Imlygic: